
Florian Naudet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8981220/publications.pdf Version: 2024-02-01



FLORIAN NALIDET

#	Article	IF	CITATIONS
1	Assessing scientists for hiring, promotion, and tenure. PLoS Biology, 2018, 16, e2004089.	2.6	244
2	Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in <i>The BMJ</i> and <i>PLOS Medicine</i> . BMJ: British Medical Journal, 2018, 360, k400.	2.4	146
3	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncology, 2016, 18, 1297-1303.	0.6	135
4	Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network metaâ€enalyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction, 2018, 113, 220-237.	1.7	117
5	Potential Reporting Bias in Neuroimaging Studies of Sex Differences. Scientific Reports, 2018, 8, 6082.	1.6	109
6	Repetitive transcranial magnetic stimulation over the orbitofrontal cortex for obsessive-compulsive disorder: a double-blind, crossover study. Translational Psychiatry, 2014, 4, e436-e436.	2.4	102
7	Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. PLoS Medicine, 2015, 12, e1001924.	3.9	84
8	US Food and Drug Administration approval of esketamine and brexanolone. Lancet Psychiatry,the, 2019, 6, 975-977.	3.7	66
9	The nucleus accumbens: a target for deep brain stimulation in resistant major depressive disorder. Journal of Molecular Psychiatry, 2013, 1, 17.	2.0	58
10	Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate. European Neuropsychopharmacology, 2014, 24, 1229-1239.	0.3	56
11	Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ: British Medical Journal, 2019, 367, l6015.	2.4	53
12	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Network Open, 2020, 3, e2024406.	2.8	53
13	Antidepressant Response in Major Depressive Disorder: A Meta-Regression Comparison of Randomized Controlled Trials and Observational Studies. PLoS ONE, 2011, 6, e20811.	1.1	51
14	Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 675-687.	1.8	47
15	Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Multiple Sclerosis Journal, 2014, 20, 1252-1259.	1.4	45
16	Overlapping network meta-analyses on the same topic: survey of published studies. International Journal of Epidemiology, 2017, 46, 1999-2008.	0.9	43
17	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	41
18	Interpretation of epidemiologic studies very often lacked adequate consideration of confounding. Journal of Clinical Epidemiology, 2018, 93, 94-102.	2.4	40

#	Article	IF	CITATIONS
19	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	38
20	Clinical application of mesenchymal stem cells in periodontal regeneration: A systematic review and metaâ€analysis. Journal of Periodontal Research, 2020, 55, 1-12.	1.4	37
21	Obsessive Compulsive Disorder Networks: Positron Emission Tomography and Neuropsychology Provide New Insights. PLoS ONE, 2013, 8, e53241.	1.1	35
22	Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. BMC Medicine, 2019, 17, 174.	2.3	34
23	A survey of biomedical journals to detect editorial bias and nepotistic behavior. PLoS Biology, 2021, 19, e3001133.	2.6	32
24	Specific and non-specific effects of psychotherapeutic interventions for depression: Results from a meta-analysis of 84 studies. Journal of Psychiatric Research, 2017, 87, 95-104.	1.5	31
25	Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. BMJ Evidence-Based Medicine, 2019, 24, 231-238.	1.7	27
26	Funders' data-sharing policies in therapeutic research: A surveyÂof commercial and non-commercial funders. PLoS ONE, 2020, 15, e0237464.	1.1	27
27	Data-sharing recommendations in biomedical journals and randomised controlled trials: an audit of journals following the ICMJE recommendations. BMJ Open, 2020, 10, e038887.	0.8	27
28	Controlled Attenuation Parameter and Liver Stiffness Measurements for Steatosis Assessment in the Liver Transplant of Brain Dead Donors. Transplantation, 2015, 99, 1619-1624.	0.5	24
29	Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVIDâ€19 pandemic. Fundamental and Clinical Pharmacology, 2020, 34, 389-396.	1.0	23
30	Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis. Sexual Medicine Reviews, 2016, 4, 257-269.	1.5	22
31	Excess Significance Bias in Repetitive Transcranial Magnetic Stimulation Literature for Neuropsychiatric Disorders. Psychotherapy and Psychosomatics, 2019, 88, 363-370.	4.0	22
32	Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer. Medicine (United States), 2016, 95, e3873.	0.4	21
33	Status, use and impact of sharing individual participant data from clinical trials: a scoping review. BMJ Open, 2021, 11, e049228.	0.8	21
34	Open science practices in clinical psychology journals: An audit study Journal of Abnormal Psychology, 2019, 128, 510-516.	2.0	21
35	Medical journal requirements for clinical trial data sharing: Ripe for improvement. PLoS Medicine, 2021, 18, e1003844.	3.9	21
36	Are There Factors Predictive of Postoperative Complications in Circumferential Contouring of the Lower Trunk? A Meta-Analysis. Aesthetic Surgery Journal, 2016, 36, 1143-1154.	0.9	20

#	Article	IF	CITATIONS
37	How the new European data protection regulation affects clinical research and recommendations?. Therapie, 2019, 74, 31-42.	0.6	20
38	Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up. Parkinsonism and Related Disorders, 2017, 34, 20-25.	1.1	19
39	Manic switches induced by antidepressants: an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatrica Scandinavica, 2017, 135, 106-116.	2.2	19
40	Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions. Epidemiology and Psychiatric Sciences, 2020, 29, e184.	1.8	19
41	Which placebo to cure depression? A thought-provoking network meta-analysis. BMC Medicine, 2013, 11, 230.	2.3	18
42	Has evidence-based medicine left quackery behind?. Internal and Emergency Medicine, 2015, 10, 631-634.	1.0	18
43	Characteristics of available studies and dissemination of research using major clinical data sharing platforms. Clinical Trials, 2021, 18, 657-666.	0.7	18
44	Evaluation in alcohol use disorders – insights from the nalmefene experience. BMC Medicine, 2016, 14, 119.	2.3	17
45	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Trials, 2018, 19, 505.	0.7	17
46	Impulsive oculomotor action selection in Parkinson's disease. Neuropsychologia, 2017, 95, 250-258.	0.7	15
47	Baclofen and alcohol in France. Lancet Psychiatry,the, 2018, 5, 961-962.	3.7	15
48	Urinary TIMPâ€2 and MMPâ€2 are significantly associated with poor bladder compliance in adult patients with spina bifida. Neurourology and Urodynamics, 2019, 38, 2151-2158.	0.8	14
49	Challenging the promotion of antidepressants for nonsevere depression. Acta Psychiatrica Scandinavica, 2019, 139, 294-295.	2.2	14
50	Improving study design for antidepressant effectiveness assessment. International Journal of Methods in Psychiatric Research, 2013, 22, 217-231.	1.1	13
51	Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry,the, 2021, 8, 11-13.	3.7	12
52	An open science pathway for drug marketing authorization—Registered drug approval. PLoS Medicine, 2021, 18, e1003726.	3.9	12
53	Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study. BMJ Open, 2022, 12, e051042.	0.8	12
54	Increase value and reduce waste in research on psychological therapies. Behaviour Research and Therapy, 2019, 123, 103479.	1.6	11

#	Article	IF	CITATIONS
55	Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials. European Journal of Clinical Pharmacology, 2019, 75, 603-607.	0.8	11
56	The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports. Epidemiology and Psychiatric Sciences, 2020, 29, e120.	1.8	11
57	Data Sharing and Reanalyses Among Randomized Clinical Trials Published in Surgical Journals Before and After Adoption of a Data Availability and Reproducibility Policy. JAMA Network Open, 2022, 5, e2215209.	2.8	10
58	Publication by association: how the COVID-19 pandemic has shown relationships between authors and editorial board members in the field of infectious diseases. BMJ Evidence-Based Medicine, 2022, 27, 133-136.	1.7	9
59	Overlapping network metaâ€analyses on psoriasis systemic treatments, an overview: quantity does not make quality. British Journal of Dermatology, 2022, 187, 29-41.	1.4	9
60	How do they add up? The interaction between the placebo and treatment effect: A systematic review. British Journal of Clinical Pharmacology, 2022, 88, 3638-3656.	1.1	9
61	Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports. BMC Medicine, 2022, 20, 177.	2.3	9
62	Subthalamic nucleus modulates social and anxogenic-like behaviors. Behavioural Brain Research, 2013, 252, 356-362.	1.2	8
63	Influence of subthalamic deep-brain stimulation on cognitive action control in incentive context. Neuropsychologia, 2016, 91, 519-530.	0.7	8
64	Evaluating Cognitive Action Control Using Eye-Movement Analysis: An Oculomotor Adaptation of the Simon Task. Frontiers in Human Neuroscience, 2016, 10, 84.	1.0	7
65	Nalmefene for alcohol dependence: a NICE decision?. Lancet Psychiatry,the, 2016, 3, 1104-1105.	3.7	7
66	Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?. Pharmacopsychiatry, 2016, 49, 260-261.	1.7	7
67	Defending psychiatry or defending the trivial effects of therapeutic interventions? A citation content analysis of an influential paper. Epidemiology and Psychiatric Sciences, 2018, 27, 230-239.	1.8	7
68	Repetitive transcranial magnetic stimulation for depression: The non-inferiority extrapolation. Journal of Affective Disorders, 2019, 254, 124-126.	2.0	7
69	Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?. Alcohol and Alcoholism, 2020, 55, 49-50.	0.9	6
70	Restoring the Bacloville trial: efficacy and harms. Addiction, 2020, 115, 2184-2186.	1.7	6
71	Approval of esketamine for treatment-resistant depression – Authors' reply. Lancet Psychiatry,the, 2020, 7, 235-236.	3.7	6
72	Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease. Journal of Neurology, 2015, 262, 881-889.	1.8	5

#	Article	IF	CITATIONS
73	Enhanced Impulsive Action Selection in Middle-Aged Adults—Insights From an Oculomotor Simon Task. Frontiers in Aging Neuroscience, 2016, 8, 251.	1.7	5
74	Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?. Alcohol and Alcoholism, 2016, 51, 623-624.	0.9	5
75	Baclofen and the "first do not harm―motto: a new French paradox?. Clinical Toxicology, 2018, 56, 307-308.	0.8	5
76	Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trials. International Journal of Methods in Psychiatric Research, 2019, 28, e1779.	1.1	5
77	Challenges with benchmarking of MDMA-assisted psychotherapy. Nature Medicine, 2021, 27, 1689-1690.	15.2	5
78	Ultrasound Biomicroscopy of the Ciliary Body in Ocular/Oculodermal Melanocytosis. American Journal of Ophthalmology, 2013, 156, 627-628.	1.7	4
79	Community treatment orders for patients with psychosis. Lancet, The, 2013, 382, 501-502.	6.3	4
80	The fallacy of thresholds used in defining response and remission in depression rating scales. International Journal of Methods in Psychiatric Research, 2014, 23, 469-473.	1.1	4
81	Influence of promised rewards on conflict resolution in healthy participants and patients with Parkinson's disease. Journal of the Neurological Sciences, 2016, 367, 38-45.	0.3	4
82	Baclofen and alcohol use disorders: From miracle to mirage. European Neuropsychopharmacology, 2017, 27, 691-692.	0.3	4
83	Post-retrieval Tetris should not be likened to a â€~cognitive vaccine'. Molecular Psychiatry, 2018, 23, 1972-1973.	4.1	4
84	Intent to share Annals of Internal Medicine's trial data was not associated with data re-use. Journal of Clinical Epidemiology, 2021, 137, 241-249.	2.4	4
85	Quality of evidence of the efficacy of therapeutic interventions on patient-important outcomes in Cochrane's systematic reviews' abstracts: A survey. Therapie, 2021, 76, 403-408.	0.6	4
86	Meta-research studies should improve and evaluate their own data sharing practices. Journal of Clinical Epidemiology, 2022, 149, 183-189.	2.4	4
87	Does reductio ad absurdumhave a place in evidence-based medicine?. BMC Medicine, 2014, 12, 106.	2.3	3
88	A randomised cross-over study assessing the "blue pyjama syndrome―in major depressive episode. Scientific Reports, 2017, 7, 2629.	1.6	3
89	Research transparency promotion by surgical journals publishing randomised controlled trials: a survey. Trials, 2020, 21, 824.	0.7	3
90	Antipsychiatry and the antidepressants debate. Lancet Psychiatry, the, 2014, 1, 173-174.	3.7	2

#	Article	IF	CITATIONS
91	Exploring "psychic transparency―during pregnancy: a mixed-methods approach. BMC Women's Health, 2016, 16, 55.	0.8	2
92	Equivalence of Psychodynamic Therapy to Other Established Treatments: Limited Supporting Evidence and Clinical Relevance. American Journal of Psychiatry, 2017, 174, 1122-1123.	4.0	2
93	Meta-Analyses and the Janus Effect. Psychotherapy and Psychosomatics, 2020, 89, 50-50.	4.0	2
94	Depot aripiprazole: subverted trials and authorisation of a best-selling drug. SSRN Electronic Journal, 0, , .	0.4	2
95	Clinical trials during pandemics and beyond: time for a more efficient pharmacological strategy. Journal of Antimicrobial Chemotherapy, 2021, 76, 2234-2236.	1.3	2
96	Letter to the editor: Covid-19 and Vit-D: Disease mortality negatively correlates with sunlight exposure. Spatial and Spatio-temporal Epidemiology, 2020, 35, 100373.	0.9	2
97	Antidepressants are not safe during pregnancy and in women of childâ€bearing age. British Journal of Clinical Pharmacology, 2022, 88, 2447-2448.	1.1	2
98	À propos des contestations d'ordre médical par les assurés sociaux. Étude transversale descriptive d'expertises L. 141-1Âdu code de la Sécurité Sociale. Archives Des Maladies Professionnelles Et De L'Environnement, 2014, 75, 43-52.	0.1	1
99	Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder. Therapie, 2015, 70, 321-327.	0.6	1
100	The learning curve effect on embolization of cerebral dural arteriovenous fistula single-center experience in 48Âconsecutive patients. Journal of Neuroradiology, 2017, 44, 52-56.	0.6	1
101	Bias in the reporting of harms in clinical trials of second-generation antidepressants: The tip of the iceberg?. European Neuropsychopharmacology, 2017, 27, 289-290.	0.3	1
102	Letter to the Editor: No Baclofen for Alcohol Use Disorders Even More When Liver Disease Is Serious!. Hepatology, 2019, 69, 2713-2713.	3.6	1
103	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117.	1.2	1
104	Is large-scale population screening coming to psychiatry?. The Lancet Digital Health, 2020, 2, e210-e211.	5.9	1
105	Nalmefene in alcoholâ€dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption. Psychiatry and Clinical Neurosciences, 2020, 74, 218-218.	1.0	1
106	Reply to the Letter to the Editor: "Mixing Apples and Oranges in Assessing Outcomes of Repetitive Transcranial Stimulation Meta-Analyses― Psychotherapy and Psychosomatics, 2020, 89, 108-108.	4.0	1
107	Social media attention and citations of published outputs from re-use of clinical trial data: a matched comparison with articles published in the same journals. BMC Medical Research Methodology, 2021, 21, 119.	1.4	1
108	Alcoholâ€related liver disease treatment and <scp>EBM</scp> . Liver International, 2022, 42, 1909-1909.	1.9	1

#	Article	IF	CITATIONS
109	Can a â€~true' effect be built on a â€~wrong' model?. British Journal of Psychiatry, 2012, 200, 512-512.	1.7	Ο
110	Comments on "What is Wrong With Systematic Reviews and Meta-Analyses: If You Want the Right Answer, Ask the Right Question!― Aesthetic Surgery Journal, 2017, 37, NP22-NP23.	0.9	0
111	The YOMEGA non-inferiority trial. Lancet, The, 2019, 394, 1411-1412.	6.3	Ο
112	Pharmacotherapies for Alcohol Use Disorder: Over Both Sides of the Atlantic Ocean. Mayo Clinic Proceedings, 2020, 95, 2294-2295.	1.4	0
113	Esketamine for treatment-resistant depression in adults. The Cochrane Library, 2022, 2022, .	1.5	0
114	Tolerability of duloxetine in elderly and in non-elderly adults: a protocol of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials. Systematic Reviews, 2022, 11, 71.	2.5	0
115	Title is missing!. , 2020, 15, e0237464.		0
116	Title is missing!. , 2020, 15, e0237464.		0
117	Title is missing!. , 2020, 15, e0237464.		Ο